AnaptysBio (NASDAQ:ANAB) Shares Up 6.6%

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) traded up 6.6% during mid-day trading on Wednesday . The stock traded as high as $25.76 and last traded at $25.54. 144,172 shares were traded during trading, a decline of 56% from the average session volume of 330,698 shares. The stock had previously closed at $23.95.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of AnaptysBio from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Monday, April 1st. Wells Fargo & Company assumed coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They set an "overweight" rating and a $56.00 price target for the company. Stifel Nicolaus initiated coverage on shares of AnaptysBio in a research report on Wednesday, February 21st. They set a "buy" rating and a $50.00 price target for the company. SVB Leerink initiated coverage on shares of AnaptysBio in a research report on Tuesday, April 16th. They issued an "outperform" rating and a $47.00 target price for the company. Finally, Wedbush reaffirmed an "outperform" rating and issued a $34.00 target price on shares of AnaptysBio in a research report on Friday, May 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.38.

AnaptysBio Stock Performance

The business's 50-day moving average price is $22.85 and its 200-day moving average price is $21.51. The stock has a market cap of $684.09 million, a P/E ratio of -4.08 and a beta of -0.32.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating analysts' consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. The company had revenue of $9.01 million for the quarter, compared to analysts' expectations of $3.28 million. As a group, equities research analysts expect that AnaptysBio, Inc. will post -6.14 earnings per share for the current year.

Insider Activity at AnaptysBio

In related news, CEO Daniel Faga sold 145,940 shares of AnaptysBio stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the transaction, the chief executive officer now owns 752,087 shares in the company, valued at approximately $17,132,541.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 33.70% of the stock is owned by corporate insiders.

Institutional Trading of AnaptysBio

Several hedge funds have recently bought and sold shares of ANAB. Allspring Global Investments Holdings LLC purchased a new stake in AnaptysBio in the 1st quarter worth $38,000. China Universal Asset Management Co. Ltd. lifted its stake in AnaptysBio by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company's stock worth $66,000 after purchasing an additional 2,390 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of AnaptysBio by 134.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company's stock valued at $106,000 after buying an additional 3,381 shares in the last quarter. Quest Partners LLC purchased a new stake in shares of AnaptysBio during the 4th quarter valued at about $119,000. Finally, SG Americas Securities LLC purchased a new stake in shares of AnaptysBio during the 4th quarter valued at about $126,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.